Pricing Log in Create free account

Enliven Therapeutics, Inc. (ELVN) vs Telix Pharmaceuticals Limited (TLX)

Enliven Therapeutics, Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Enliven Therapeutics, Inc. and Telix Pharmaceuticals Limited are of similar size ($3.3B and $3.2B). Across the 7 metrics below, Enliven Therapeutics, Inc. leads on 4 and Telix Pharmaceuticals Limited on 3.

Valuation

Metric ELVN TLX Biotechnology median
P/E n/m — 10.26
P/S n/m — 9.18
P/B 3.34 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 8.98
Earnings yield (3.69%) — (34.89%)
Free cash flow yield (2.24%) 0.00% (24.52%)

Profitability

Metric ELVN TLX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (15.31%) 0.00% (50.12%)
Return on assets (14.98%) 0.00% (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ELVN TLX Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) 3.17% (120.00%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ELVN TLX Biotechnology median
Debt to equity 0.00 1.18 0.00
Current ratio 64.07 2.01 4.89
Net debt to EBITDA 3.87 6.25 1.01

Dividend

Metric ELVN TLX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ELVN TLX Biotechnology median
Market cap 3.28b 3.21b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack